Lower immune response in HIV‐positive girls to the quadrivalent human papillomavirus vaccine | Jason Brophy, MD

International Workshop on HIV & Pediatrics 2015

Hearing Loss in HIV‐Infected Children in Lilongwe, Malawi | Susan Hrapcak, MD

International Workshop on HIV & Pediatrics 2015

Hepatitis C virus infection in children with and without HIV ‐ Treatment | Giuseppe Indolfi, MD, PhD

International Workshop on HIV & Pediatrics 2015

Hepatitis C virus Infection in Children with and without HIV ‐ Epidemiologynsmission (MTCT) of HIV during Breastfeeding (BF) | Claire Thorne, BA, MSc, PhD

International Workshop on HIV & Pediatrics 2015

Controversies in TB Meningitis | Kelly Dooley, MD, PhD

International Workshop on HIV & Pediatrics 2015

Debate: HIV‐Exposed Uninfected Infants Require Lifelong Follow Up in All

International Workshop on HIV & Pediatrics 2015

Round Table Discussion: HIV testing at birth: potential benefits, risks and feasibility | Ellen Chadwick, MD

International Workshop on HIV & Pediatrics 2015

Second‐line ART treatment and resistance outcomes of Asian children | Annette Sohn, MD

International Workshop on HIV & Pediatrics 2015

Bridging Worlds: Perinatally‐Infected Youth and Transition to Adult Care | Caroline Foster, MBBS, MRCPCH

International Workshop on HIV & Pediatrics 2015

Innovative Adherence Interventions for HIV‐Infected Youth | Rachel Vreeman, MD, MS

International Workshop on HIV & Pediatrics 2015

Debate: CD4 Assays Are No Longer Needed for Care of Children in Lowresource Countries

International Workshop on HIV & Pediatrics 2015

Pediatric Treatment Cascade: What Do We Need to Reach “90‐90‐90” for Children | Elaine Abrams, MD

International Workshop on HIV & Pediatrics 2015

TDF Use Across the Age Spectrum: From Fetus to Adolescent - Anna Turkova, MD

International Workshop on HIV & Pediatrics 2015

Debate: CD4 Assays Are No Longer Needed for Care of Children in Lowresource Countries - Ted Ruel, MD

International Workshop on HIV & Pediatrics 2015

CON ‐ standpoint - Diana Gibb, MD, MRCP, MSc

International Workshop on HIV & Pediatrics 2015

Pediatric Treatment Cascade: What Do We Need to Reach “90‐90‐90” for Children - Elaine Abrams, MD

International Workshop on HIV & Pediatrics 2015

Virologic Outcomes of Children Switched from Lopinavir/Ritonavir‐ to Efavirenz‐Based Antiretroviral Treatment: a retrospective cohort study - Kirsten Reichmuth

International Workshop on HIV & Pediatrics 2015

Lopinavir ritonavir (1:1 ratio) in the presence of rifampicin is not inferior to lopinavir ritonavir (4:1 ratio) in the absence of rifampicin in HIV children. Interim analysis of an open label sequential non- randomized phar- Mark Cotton

International Workshop on HIV & Pediatrics 2015

The effect of systemic exposure to efavirenz, sex and age on the risk of virological non‐suppression in HIV‐infected African children - Andrzej Bienczak

International Workshop on HIV & Pediatrics 2015

Durability of first‐line antiretroviral therapy (ART) in children in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) - Ruth Goodall

International Workshop on HIV & Pediatrics 2015

Reasons for delayed ART initiation in children with HIV in South Africa - Chloe Teasdale

International Workshop on HIV & Pediatrics 2015

Efavirenz‐based therapy may simplify antiretroviral LPV‐based therapy initiated in HIV‐1‐infected children before the age of 2 in West‐Africa: the MONOD trial ANRS 12206 - Valeriane Leroy

International Workshop on HIV & Pediatrics 2015

Bridging Worlds: Perinatally‐Infected Youth and Transition to Adult Care - Caroline Foster, MBBS, MRCPCH

International Workshop on HIV & Pediatrics 2015

Anxiety and depression in young people with perinatal HIV and their HIV negative siblings - Marthe Le Prevost

International Workshop on HIV & Pediatrics 2015